David Richardson
Ophthalmology · San Marino, CANPI 1578553921
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,500 of the $25,138 with a category attached, or 65.6%. Ellexiscience accounts for 85.8% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $22,185 and has fallen 96.3% since, to $817 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 68 payments — averaging $369.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ellexiscience$22K
- Alcon$649
- Carl Zeiss Meditec USA, Inc.$588
- Sight Sciences, Inc.$530
- Bausch & Lomb, A Division Of Bausch Health US, LLC$476
- AbbVie$249
- plus $1K from 13 others
What the payments were for
- Speaking & faculty fees$16,50066%
- Travel & lodging$5,06420%
- Food & beverage$2,92212%
- Gifts$640%
- Other$5882%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ellexiscience | 2 | $21,564 |
| Alcon | 21 | $649 |
| Carl Zeiss Meditec USA, Inc. | 2 | $588 |
| Sight Sciences, Inc. | 11 | $530 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $476 |
| AbbVie | 5 | $249 |
| Glaukos Corporation | 6 | $211 |
| Bausch & Lomb Americas Inc. | 3 | $166 |
| Rxsight Inc | 2 | $161 |
| Ivantis, Inc | 1 | $154 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $117 |
| Lumibird Medical Inc. | 1 | $87 |
| Sun Pharmaceutical Industries Inc. | 2 | $65 |
| LKC Technologies, Inc. | 1 | $23 |
| Aerie Pharmaceuticals, Inc. | 1 | $23 |
| Novartis | 1 | $20 |
| Thea Pharma Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Ocular Therapeutix, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$445
- STELLARIS$250
- ENVISTA$250
- Hydrus$154
- Luxor$150
- NGENUITY$150
- RXSIGHT CONTACT LENS$136
- RXSIGHT INJECTOR CARTRIDGE$136
- RXSIGHT INJECTOR HANDPIECE$136
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$136
- LIGHT ADJUSTABLE LENS (LAL)$136
- MIEBO$125
- XIIDRA$125
- Rocklatan$125
- Rhopressa$125
- TRYPTYR$125
- ENVISTA TORIC$124
- Tecnis IOL$117
How this compares
$25,138 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 43 | $33,099 |
| RhopressaNetarsudil Mesylate | 36 | $21,689 |
| RestasisCyclosporine | 14 | $19,055 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 45 | $15,613 |
| LumiganBimatoprost | 28 | $14,616 |
| RocklatanNetarsudil Mesylat/Latanoprost | 19 | $11,416 |
| Brimonidine Tartrate | 32 | $10,597 |
| Alphagan PBrimonidine Tartrate | 15 | $9,986 |
| VevyeCyclosporine | 12 | $8,808 |
| Restasis MultidoseCyclosporine | 11 | $6,978 |
| Travoprost | 23 | $5,169 |
| VyzultaLatanoprostene Bunod | 12 | $5,023 |
| Brinzolamide | 14 | $3,731 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $2,458 |
| Betaxolol Hcl | 17 | $1,529 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Restasis Multidose | $249 | $50,63568 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $166 | $38,12355 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $23 | $33,10455 claims |
| AlconSimbrinza | $649 | $15,61345 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in San Marino
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.